← Back to Research Radar
Academic Publication Academic Publication

Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning

96
Citations
May 9, 2024
Published Date

Research Abstract & Technology Focus

AbstractEstimating protein targets of compounds based on the similarity principle—similar molecules are likely to show comparable bioactivity—is a long-standing strategy in drug research. Having previously quantified this principle, we present here a large-scale evaluation of its predictive power for inferring macromolecular targets by reverse screening an unprecedented vast external test set of more than 300,000 active small molecules against another bioactivity set of more than 500,000 compounds. We show that machine-learning can predict the correct targets, with the highest probability among 2069 proteins, for more than 51% of the external molecules. The strong enrichment thus obtained demonstrates its usefulness in supporting phenotypic screens, polypharmacology, or repurposing. Moreover, we quantified the impact of the bioactivity knowledge available for proteins in terms of number and diversity of actives. Finally, we advise that developers of such approaches follow an application-oriented benchmarking strategy and use large, high-quality, non-overlapping datasets as provided here.
testing predictive power reverse screening infer
Read Full Literature

Correlated Market Trend: A/b Testing

Bridging academia to market: The 60-day public search velocity mapping directly to the core technology of this paper. Dashed line represents 7-day moving average.

AI Semantic Synergy Context

Connecting this academic literature to real-world market discussions and products.

crossref.org › academic paper
74%
🔥

Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning

AbstractEstimating protein targets of compounds based on the similarity principle—similar molecules are likely to show comparable bioactivity—is a long-standing strategy in drug research. Having pr...
crossref.org › academic paper
0%

Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction

Abstract Evaluating pharmacokinetic properties of small molecules is considered a key feature in most drug development and high-throughput screening processes. Generally, pharmacokin...
crossref.org › academic paper
0%

Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development

AbstractDespite increasing interest in using Artificial Intelligence (AI) and Machine Learning (ML) models for drug development, effectively interpreting their predictions remains a challenge, whic...
crossref.org › academic paper
0%

ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries

Abstract Motivation The emergence of large chemical repositories and combinatorial chemical spaces, coupled with high-throughput docking a...
crossref.org › academic paper
0%

Predictive modeling for breast cancer classification in the context of Bangladeshi patients by use of machine learning approach with explainable AI

AbstractBreast cancer has rapidly increased in prevalence in recent years, making it one of the leading causes of mortality worldwide. Among all cancers, it is by far the most common. Diagnosing th...

Frequently Asked Questions (FAQ)

Curated market intelligence mapped to this research.

What is the core focus of the research titled 'Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning'?

This literature focuses on: AbstractEstimating protein targets of compounds based on the similarity principle—similar molecules are likely to show comparable bioactivity—is a long-standing strategy in drug research. Having previously quantified this principle, we present her...

Are there open-source GitHub repositories related to Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning?

Yes, open-source projects like gsd-build/gsd-2 (A powerful meta-prompting, context engineering and spec-driven development system that enables agents to work for long periods of time autonomously...) are actively building upon these concepts.

Which startups are commercializing the technology behind Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning?

Products like FreeCAD 1.1 are bringing this to market. Their focus is: Extremely powerful, completely free 3D CAD modeling.

What other academic literature is closely related to 'Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning'?

Yes, highly correlated activity was mapped. An entry titled 'Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning' discusses this: AbstractEstimating protein targets of compounds based on the similarity principle—similar molecules are likely to show comparable bioactivity—is a ...

Cite this Market Intelligence Report

Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.

Commercial Realization

Startups and Open Source tools heavily associated with the concepts explored in this paper.

Associated Media Narrative